NCT06323889Recruiting
Longitudinal Monitoring During Intermittent Fasting Protocols in Obese Adults
Longitudinal Monitoring During Different Intermittent Fasting Protocols in Obese Adults - a Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 20 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
LIMITFOOD2 is a randomized clinical intervention study that investigates the effects of two different intermittent fasting protocols compared to a control group on the health of obese adults. A total of 90 participants will be randomized into three equally sized groups: a modified alternate day fasting, a time-restricted eating and a control group, receiving general weight-loss counseling.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 6 Mar 2024
- Start date
- 23 Sept 2024
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- University of Zurich
- Diseases
- Obesity
- NCT number
- NCT06323889
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 23 Sept 2024 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Antibiotics intake during 3 months prior to the study due to possible interference with metabolic parameters
- Known alcohol, substance or drug abuse, concomitant medication
- Therapy with antidepressants within the past 6 months
- Regular therapy with acetylsalicyclic acid or current medication to regulate blood sugar, blood pressure or lipids
Other illness
- Food intolerances, allergies and sensitivities (severe food allergies) or dietary restrictions (e.g. vegan lifestyle)
- Diabetes
Lab values
- Acute or chronic infections, malignant disease, renal, hepatic (more than two-fold increased transaminases), pulmonary, neurological (epilepsy) or psychiatric diseases, manifested atherosclerosis, or any other disease precluding participation in the study.
Other
- Participants who have a fasting period of \> 12h per day on a regular basis and do not eat at least three main meals per day.
- Current habitual use of dietary supplements (e.g., vitamins, minerals) and/or unwillingness to cease intake of dietary supplements.
- More than four hours of physical exercise per week
- Women who are pregnant, breast-feeding or aiming to become pregnant during course of the trial
- Women and men on hormonal supplementation
- Women with an irregular menstrual cycle according to the FIGO criteria
- Participants likely to fail to comply with the study protocol
- Participants who do not give informed consent
Who the study is looking for
- Age between 18-50 years, both inclusive
- Obese, BMI between 30 and 40 kg/m\^2 (obesity grade I or II), both inclusive
- Non-smoker
- Good knowledge of German or English language
- Stable weight change (change \< +/- 3% current bodyweight) for 3 months prior to the study
- HbA1c \< 6.5% without glucose lowering medication
- LDL-cholesterol \< 4.6mmol/l without lipid lowering medication
Age in the registry: 18 years to 50 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Endocrinology, Diabetology and Clinical Nutrition Coordinator of this site? Confirm its status | Zurich | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.